Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Perceived Stigma, Psychological Distress, and Symptom Burden in Decompensated Cirrhosis.

Journal of pain and symptom management·2026

Same author

Corporations and financial institutions driving coastal conflicts involving Indigenous Peoples.

Ambio·2026

Same author

Mixed Autoimmune Hemolytic Anemia With Refractory Cold Agglutinin Syndrome in a Child Successfully Treated With Serial Whole Blood Exchange Transfusions and Immunosuppression.

Journal of pediatric hematology/oncology·2026

Same author

A 3D multi-compartment assembloid to study combined immune cell infiltration and cytotoxicity.

Cell reports methods·2026

Same author

Indigenous Peoples and local communities as agents of transformative change for sustainability.

Communications earth & environment·2026

Same author

Transformative change to address biodiversity loss is urgent and possible.

PLoS biology·2025

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Traumatic bleeding at birth treated with Factor VII.

Kathryn A Browning Carmo¹, Karen O'Brien, Juliana Teo

¹Grace Centre for Newborn Care, Children's Hospital at Westmead and University of Sydney, Australia. kathryc4@chw.edu.au

Journal of Paediatrics and Child Health

|February 12, 2009

Summary

A traumatic delivery resulted in twins requiring intervention. Recombinant Factor VIIa successfully controlled severe bleeding in Twin 2, demonstrating its efficacy in obstetric emergencies.

More Related Videos

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Related Experiment Videos

Last Updated: Jun 25, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Area of Science:

Obstetrics and Gynecology
Hematology
Neonatal Medicine

Background:

Traumatic deliveries can lead to severe postpartum hemorrhage.
Hemostatic agents are crucial for managing life-threatening bleeding in neonates.
Recombinant activated Factor VII (rFVIIa) is a potential treatment for severe hemorrhage.

Observation:

A case of 36-week gestation twins born after a traumatic delivery is presented.
Twin 2 experienced profuse hemorrhage following birth.
Standard hemostatic measures were insufficient.

Findings:

Hemostasis was successfully achieved in Twin 2 using recombinant Factor VIIa (rFVIIa).
The administration of rFVIIa (NovoSeven) effectively controlled the severe bleeding.
This case highlights the successful application of rFVIIa in a neonatal obstetric complication.

Implications:

Recombinant Factor VIIa can be a life-saving option for severe neonatal hemorrhage post-traumatic delivery.
This case supports the consideration of rFVIIa in managing refractory obstetric bleeding in neonates.
Further research may explore the optimal use of rFVIIa in similar critical obstetric scenarios.